Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BDB-001 in healthy subjects
NCT05360927Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BDB-001 in coronavirus disease 2019 (COVID-19) and Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (7 arms), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically… up to 50 days, Maximum plasma concentration and 7 more. Started Sep 2019; status: completed.
02
Drugs
BDB-001
03
Conditions
coronavirus disease 2019 (COVID-19)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05360927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360927.